These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 15372850)

  • 1. Therapeutic implications of macrolide resistance in pneumococcal community-acquired lower respiratory tract infections.
    Marrie TJ
    Int J Clin Pract; 2004 Aug; 58(8):769-76. PubMed ID: 15372850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hidden epidemic of macrolide-resistant pneumococci.
    Klugman KP; Lonks JR
    Emerg Infect Dis; 2005 Jun; 11(6):802-7. PubMed ID: 15963272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
    Feldman C
    J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of macrolides in treatment of upper respiratory tract infections.
    Wierzbowski AK; Hoban DJ; Hisanaga T; DeCorby M; Zhanel GG
    Curr Allergy Asthma Rep; 2006 Mar; 6(2):171-81. PubMed ID: 16566868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical management of respiratory tract infections in the community: experience with telithromycin.
    Quintiliani R
    Infection; 2001 Dec; 29 Suppl 2():16-22. PubMed ID: 11785852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Telithromycin: the first ketolide antibacterial for the treatment of community-acquired respiratory tract infections.
    Lorenz J
    Int J Clin Pract; 2003; 57(6):519-29. PubMed ID: 12918892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Macrolide resistance: an increasing concern for treatment failure in children.
    Jacobs MR; Johnson CE
    Pediatr Infect Dis J; 2003 Aug; 22(8 Suppl):S131-8. PubMed ID: 14566999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of antibiotic resistance in respiratory tract infections.
    Klugman KP
    Int J Antimicrob Agents; 2007 Feb; 29 Suppl 1():S6-10. PubMed ID: 17307654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug treatment of pneumococcal pneumonia in the elderly.
    Neralla S; Meyer KC
    Drugs Aging; 2004; 21(13):851-64. PubMed ID: 15493950
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of azithromycin in the treatment of community-acquired pneumonia, including patients with macrolide-resistant Streptococcus pneumoniae infection.
    Yanagihara K; Izumikawa K; Higa F; Tateyama M; Tokimatsu I; Hiramatsu K; Fujita J; Kadota J; Kohno S
    Intern Med; 2009; 48(7):527-35. PubMed ID: 19336954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of macrolide resistance in community-acquired respiratory tract infections.
    Hoban DJ; Zhanel GG
    Expert Rev Anti Infect Ther; 2006 Dec; 4(6):973-80. PubMed ID: 17181414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Penicillin and macrolide resistance in pneumococcal pneumonia: does in vitro resistance affect clinical outcomes?
    Rothermel CD
    Clin Infect Dis; 2004 May; 38 Suppl 4():S346-9. PubMed ID: 15127368
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolving resistance patterns in community-acquired respiratory tract pathogens: first results from the PROTEKT global surveillance study. Prospective Resistant Organism Tracking and Epidemiology for the Ketolide Telithromycin.
    Felmingham D
    J Infect; 2002 Feb; 44 Suppl A():3-10. PubMed ID: 12150493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overview of antimicrobial options for Mycoplasma pneumoniae pneumonia: focus on macrolide resistance.
    Cao B; Qu JX; Yin YD; Eldere JV
    Clin Respir J; 2017 Jul; 11(4):419-429. PubMed ID: 26365811
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrolide Resistance in
    Schroeder MR; Stephens DS
    Front Cell Infect Microbiol; 2016; 6():98. PubMed ID: 27709102
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia.
    Lynch III JP; Martinez FJ
    Clin Infect Dis; 2002 Mar; 34 Suppl 1():S27-46. PubMed ID: 11810608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ketolides: an emerging treatment for macrolide-resistant respiratory infections, focusing on S. pneumoniae.
    Zhanel GG; Hisanaga T; Nichol K; Wierzbowski A; Hoban DJ
    Expert Opin Emerg Drugs; 2003 Nov; 8(2):297-321. PubMed ID: 14661991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International guidelines for the treatment of community-acquired pneumonia in adults: the role of macrolides.
    File TM; Tan JS
    Drugs; 2003; 63(2):181-205. PubMed ID: 12515565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides.
    Lonks JR; Garau J; Medeiros AA
    J Antimicrob Chemother; 2002 Dec; 50 Suppl S2():87-92. PubMed ID: 12556438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms, molecular and sero-epidemiology of antimicrobial resistance in bacterial respiratory pathogens isolated from Japanese children.
    Sunakawa K; Farrell DJ
    Ann Clin Microbiol Antimicrob; 2007 Aug; 6():7. PubMed ID: 17697316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.